## Facts

- University of Wisconsin researchers collaborated with Xenon Pharmaceuticals, Inc. (Xenon) to develop technology aimed at reducing concentrations of an enzyme associated with high cholesterol.
- Wisconsin Alumni Research Foundation (WARF), the university’s patent-management entity, and Xenon became joint owners of patent rights covering the technology.
- WARF and Xenon entered into an Exclusive License Agreement (ELA) giving Xenon exclusive rights to make, use, and sell products derived from the patented technology, while requiring Xenon to pay WARF specified percentages of royalties, product-sales revenue, and sublicense consideration.
- Xenon entered into a transaction with Novartis Pharma AG (Novartis) granting Novartis rights tied to the jointly owned patent application and related technology.
- Xenon did not pay WARF a share of the consideration Xenon received from Novartis, taking the position that it could license its undivided interest as a joint patent owner without being bound by the ELA’s sublicense-payment terms.
- WARF sued Xenon in the Western District of Wisconsin for breach of the ELA and related relief involving additional compounds developed during the parties’ relationship (often referred to as “PPA compounds”).
- On cross-motions for summary judgment, the district court ruled for WARF on the breach-of-contract issue, concluding the Novartis deal was a sublicense under the ELA and that Xenon owed WARF a share of the consideration received.
- After a jury trial on damages, the award was reduced on remittitur, and the case proceeded on appeal, ultimately reaching the United States Court of Appeals for the Seventh Circuit.

## Issues

1. Whether a joint patent owner may rely on 35 U.S.C. § 262 to grant a third-party license and keep the proceeds, despite contract terms requiring sharing of sublicense consideration with the other joint owner.
2. Whether the Xenon–Novartis transaction was a “sublicense” governed by the ELA (triggering WARF’s payment rights) rather than a license of Xenon’s separate rights outside the ELA.
3. Whether Xenon’s payment duties under the ELA were triggered when Xenon received sublicense fees and other consideration, or only later if products were actually sold.
4. Whether WARF obtained ownership/title to certain later-developed compounds (the “PPA compounds”) under the relevant agreements or federal law (including Bayh-Dole), and how that affected the parties’ financial rights.

## Decision

- The Seventh Circuit affirmed the district court’s conclusion that the ELA controlled the parties’ rights and limited Xenon’s ability to act as if § 262 allowed it to license freely while avoiding the ELA’s payment terms.
- The court affirmed that the Novartis transaction functioned as a sublicense within the meaning of the ELA, so Xenon’s receipt of Novartis consideration triggered WARF’s contractual share.
- The court affirmed that Xenon breached the ELA by granting the Novartis sublicense without meeting the ELA’s sublicense requirements and by failing to pay WARF the required percentage of sublicense consideration.
- The court rejected Xenon’s argument that no payments were due until downstream product sales occurred, holding the ELA required payment to WARF when Xenon received the relevant fees and other consideration.
- On the disputes involving the PPA compounds, the court largely agreed with the district court’s rejection of WARF’s ownership/title theories, while leaving in place the ELA-based payment obligations tied to commercialization within the agreement’s scope.
- The damages outcome (as remitted and accepted) remained intact subject to any limited adjustments not affecting the core liability rulings.

## Legal Principles

- Joint patent ownership rights under 35 U.S.C. § 262 operate as default rules and may be altered by contract between the joint owners.
- Courts enforce royalty and sublicense-fee provisions as written; a party cannot avoid payment duties by characterizing a transfer as a “license” if, in substance and by contract definition, it is a “sublicense.”
- Where a contract provides that revenue-sharing is due upon receipt of sublicense fees, milestones, or other consideration, payment is owed when the licensee receives that consideration, not only if products later reach the market.
- Federal funding statutes such as the Bayh-Dole Act do not, by themselves, automatically transfer title to disputed inventions absent the required contractual and statutory conditions.
- Contract interpretation focuses on the agreement’s text and structure, including provisions that set out available commercialization paths (direct commercialization, sublicensing with revenue sharing, or assignment with required consent).

## Conclusion

Wisconsin Alumni Research Foundation v. Xenon Pharmaceuticals held that Xenon could not invoke § 262’s default co-owner freedoms to avoid an Exclusive License Agreement requiring it to share sublicense proceeds with WARF; the Seventh Circuit treated the Novartis deal as a sublicense governed by the ELA, found Xenon in breach for failing to pay WARF its contractual share when received, and largely left intact the district court’s resolution of related ownership disputes over additional compounds while preserving ELA-based payment obligations.


Wisconsin Alumni Research Foundation v. Xenon Pharmaceuticals, 591 F.3d 876 (2010)